AVROBIO, Inc. (AVRO) Stock: Here’s What’s Happening


AVROBIO, Inc. (AVRO) is making a move up in the market in today’s trading session. The stock, one that is focused on the biotech sector, is currently priced at $15.68 after heading up 5.16% so far in today’s session. When it comes to biotech stocks, there are a number of factors that have the ability to generate movement in the market. One of the most common is news. Here are the most recent stories associated with AVRO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-05-19 07:00AM AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
Feb-06-19 09:00AM AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
Feb-05-19 02:48PM Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82%
Feb-01-19 07:00AM AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
Jan-18-19 07:43AM AVROBIO Enters Oversold Territory

However, when making a decision to invest, prospective investors should look at far more than news, especially in the speculative biotechnology industry. Here’s what’s happening in regard to AVROBIO, Inc..

Trends That We’ve Seen From AVRO

While a gain in a single session, like the move that we’re seeing from AVROBIO, Inc. may lead to excitement in some investors, a single session gain by itself should not be the basis of a decision to, or not to, invest in a company. It’s always a good idea to dig into trends beyond a single trading session. When it comes to AVRO, here are the returns that investors have seen:

  • Past 5 Sessions – Throughout the last seven days, AVRO has generated a price change in the amount of 15.72%.
  • Monthly – The performance from AVROBIO, Inc. over the past 30 days has been 14.20%.
  • Past 3 Months – Throughout the last three months, the stock has produced a ROI that comes to -35.66%
  • Past 6 Months – Over the past 6 months, we have seen a change of -57.44% from the company.
  • This Year So Far – Since the open of this year AVRO has produced a ROI of -5.83%.
  • Annually – Lastly, in the last full year, investors have seen a change that works out to 0 from AVRO. Throughout this period, the stock has sold at a high of -70.80% and a low price of 32.38%.

Crucial Ratios

Looking at a few key ratios associated with a stock can provide prospective investors a look of how dangerous and/or rewarding a stock pick might be. Here are a few of the most important ratios to think about when looking at AVRO.

Short Ratio – The short ratio is a tool that’s used by investors to measure the level of short interest. As the ratio heads up, it shows that more investors believe that the stock is going to go down. In general, biotech stocks can come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, in regard to AVROBIO, Inc., it’s short ratio amounts to 3.60.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure whether or not a company can cover its debts as they mature with only current assets or quick assets. In the biotech space, several companies are reliant on continued investor support, the current and quick ratios can look damning. Nonetheless, quite a few gems in the biotechnology sector come with positive quick and current ratios. As it relates to AVRO, the quick and current ratios add up to 25.80 and 25.80 respectively.  

Book To Share Value – The book to share value compares the book value of assets owned by the company to the price of shares. when it comes to AVROBIO, Inc., that ratio equates to 5.77.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. In this case, the cash to share value works out to 5.89.

What Analysts Say About AVROBIO, Inc.

While it’s rarely a good idea to blindly follow the thoughts of analysts, it is a good idea to use their opinions when validating your own when it comes to making an investment decision in the biotechnology sector. Below you’ll find|Here are} the recent moves that we’ve seen from analysts with regard to AVRO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-10-18 Initiated Guggenheim Buy
Oct-02-18 Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18 Initiated H.C. Wainwright Buy $47
Jul-16-18 Initiated Wells Fargo Outperform $40
Jul-16-18 Initiated Wedbush Outperform $38

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AVRO, here’s what we’re seeing:

  • Institutions – At the moment, institutional investors own 70.30% of AVRO. On the other hand, it’s worth noting that institutional ownership has seen a move of 3.91% over the past quarter.
  • Insider Holdings – When it comes to insiders, members of the management team and others close to AVRO currently own 0.10% of AVROBIO, Inc.. Their ownership of the company has changed by 0 throughout the past 3 months.

Interested In How Many Shares Are Available?

Investors seem to be interested in the counts of shares both available and outstanding. In regard to AVROBIO, Inc., there are currently 23.55M with a float of 23.08M. These data mean that of the total of 23.55M shares of AVRO in existence today, 23.08M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AVRO, the short percent of the float is 3.01%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.32. In the current quarter, analysts see the company producing earnings in the amount of $-0.57. Over the last 5 years, AVRO has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -69.00% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was created by a human and human beings play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here